New pill shows promise for Hard-to-Treat neuroendocrine tumors
NCT ID NCT03600233
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dose increase if tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CVM-1118 (also called TRX-818), an oral anti-cancer drug
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital, KaoHsiung
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital, LinKou
Taoyuan City, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- New drug cocktail aims to fight rare cancer